Recent news includes a collaboration on an innovative hair loss solution and general market news unrelated directly to the company’s core operations.

• Zeo ScientifiX announced collaboration on an innovative hair loss solution, indicating ongoing product development efforts [N1].

Zeo ScientifiX has demonstrated revenue growth in its PPX™ service platform, which now represents a significant portion of total revenues and contributes to improved gross margins. The company’s efforts to expand sales through additional representatives, marketing initiatives, and participation in industry events support business development. Collaboration on innovative solutions, such as a hair loss product, indicates active product pipeline development. The company’s non-exclusive supplier and customer agreements provide operational flexibility. Capital raising activities, including private offerings, provide working capital to support ongoing operations and growth initiatives.

The company has a history of net losses and negative operating cash flows, with substantial doubt about its ability to continue as a going concern. Revenues from higher concentration biologic products have declined due to increased competition and pricing pressures. The company’s liquidity is marginal, with a current ratio near 1.0 and cash ratio below 0.5 as of April 2026. Trading of the company’s common stock is limited and subject to penny stock rules, which may reduce market liquidity. General and administrative expenses are high relative to revenues, driven by stock-based compensation and other costs. The company faces risks related to regulatory compliance, competitive pressures, and the need for additional capital to sustain operations.

Zeo ScientifiX’s moat is based on its proprietary PPX™ service platform and its portfolio of allogenic aesthetic biologic products. The company’s PPX™ platform has shown revenue growth and higher gross margins compared to its biologic product lines. The company’s non-exclusive supply and sales agreements provide flexibility but also expose it to competition. The company’s ongoing research and development efforts aim to expand its product offerings, which may contribute to differentiation. However, the company operates in a competitive market with pricing pressures and regulatory challenges, and its limited scale and financial losses constrain its competitive positioning.

• Going Concern Risk: The company has disclosed substantial doubt about its ability to continue as a going concern due to limited revenues and ongoing net losses [S1].
• Liquidity Risk: Current liquidity ratios are marginal, with a current ratio of 1.05 and cash ratio of 0.46 as of April 30, 2026, indicating limited cushion to meet short-term obligations [sec_financial_snapshot].
• Market and Competitive Risk: Increased competition has led to decreased revenues from higher concentration biologic products and pricing pressures [S1].
• Stock Liquidity Risk: The company’s common stock trades on OTCQB with limited and sporadic activity and is subject to penny stock rules, which may reduce trading liquidity [S1].
• Regulatory and Operational Risk: The company operates in a regulated environment with ongoing research and development and compliance requirements that may impact operations and costs [S1].

• Zeo ScientifiX, Inc. operates primarily in the aesthetic biologics and service platform sector, with revenues derived from higher concentration allogenic aesthetic biologics, lower concentration allogenic aesthetic biologics, and its PPX™ service platform [S1].
• For the fiscal year ended October 31, 2025, the company reported revenues of $5.199 million, a 12.5% increase from $4.62 million in 2024, driven mainly by growth in the PPX™ service platform [S1].
• The PPX™ service platform accounted for 29.4% of revenues in 2025, up from 13.3% in 2024, reflecting increased sales efforts including additional sales representatives and marketing activities [S1].
• Revenues from higher concentration allogenic aesthetic biologics decreased due to increased competition and lower demand, while lower concentration products saw a slight increase in unit sales [S1].
• Gross profit for 2025 was $4.268 million (82.0% margin), up from $3.776 million (81.7% margin) in 2024, with margin improvements mainly from the PPX™ platform [S1].
• General and administrative expenses increased by 6.1% to $9.654 million in 2025, driven by higher stock-based compensation, lab costs, and professional fees, partially offset by reduced commissions and marketing expenses [S1].
• The company reported a net loss of $5.521 million for 2025, compared to $4.705 million in 2024, with net loss per share of $0.86 basic and diluted [S1].
• Zeo ScientifiX's common stock trades on the OTCQB market under the symbol 'ZEOX' with limited and sporadic trading activity, and is subject to penny stock rules which may affect liquidity [S1].
• As of April 30, 2026, the company had current assets of $3.266 million and current liabilities of $3.111 million, resulting in a current ratio of 1.05 and a cash ratio of 0.46, indicating marginal liquidity [sec_financial_snapshot].
• Cash and cash equivalents were $1.422 million as of January 31, 2023, with no short-term investments reported [sec_financial_snapshot].
• The company has engaged in private equity offerings, including a November 2025 private offering of units consisting of common stock and warrants, raising $1.2 million through issuance of 300,000 shares and 300,000 warrants for working capital [S1].
• Zeo ScientifiX has contracts with multiple suppliers for tissue raw materials, with no exclusive supply agreements, reducing supplier concentration risk [S1].
• The company has a finance lease obligation for lab equipment with monthly payments and options to acquire the equipment, with total finance lease liabilities of $110,000 as of October 31, 2025 [S1].
• Stock-based compensation is a significant expense, with grants to employees, advisors, and board members, amortized over vesting periods [S1].
• The company has a history of net losses and limited revenues, with substantial doubt about its ability to continue as a going concern noted in the latest annual report [S1].
• Recent news includes a collaboration on an innovative hair loss solution, indicating ongoing product development efforts [N1].